HIV/AIDS

The clinical management of patients with hepatitis C virus (HCV) infection represents an ideal opportunity for the benefits of precision medicine and the individualization of patient care. This is particularly true given the importance of genetic and nongenetic factors that have recently been identified as critical to HCV infection management.

An estimated 3.3% of people in the United States born between 1945 and 1965 have chronic hepatitis C infection. The increased risk of infection in this population has recently led the Centers for Disease Control and Prevention (CDC) to recommend one-time hepatitis C virus (HCV) testing for all persons in this age cohort.

Researchers at Temple University believe they have found a way to help remove any traces of HIV-1 from a person's body as work continues toward a cure for the virus.

While half of all HIV/AIDS patients are African American, they only comprise 30% of those enrolled in clinical trials on the disease.

The International Antiviral Society–USA Panel has released its 2014 report, which provided clinical recommendations to stop HIV transmission.

Among couples with an HIV-positive member, a study in the Cochrane Database of Systematic Reviews deemed antiretroviral therapy effective at preventing HIV transmission to the HIV-negative partner.

A team of researchers has discovered a new course of treatment that could be a major step in curing those co-infected with hepatitis C virus and HIV.

A story that captivated the medical community for the past few years has reportedly taken a bad turn, as a 4-year-old child who was previously believed to be cured of HIV is once again showing signs of the virus.

While half of all HIV/AIDS patients are African American, they only comprise 30% of those enrolled in clinical trials on the disease.

Men who have sex with men and women (MSMW) have unique vulnerability to HIV and sexually transmitted infections (STIs) and other sexual health problems, according to a review published online June 22 in American Journal of Preventive Medicine.

Even as recently as a decade ago, an HIV diagnosis could have been equivalent to a death sentence. But now, researchers are working to make a cure for the virus a reality.

Study results show hepatic decompensation is more common in people who have both HIV and hepatitis C virus (HCV) compared to those infected only with HCV, an indication that early HCV treatment among coinfected patients is needed.

During experiments with cell-to-cell and cell-free transmissions, researchers showed that existing drugs are effective in suppressing the spread of HIV.

Researchers safely infuse engineered immune cells in groundbreaking gene therapy study.

Among HIV-positive injection drug users, food insecurity is associated with mortality despite the use of antiretroviral therapy.

The American Academy of Pediatrics designed the 2014 Recommendations for Pediatrics Preventive Health Care to guide well-child care, but there is controversy over some of the changes.

A recent study has determined the immune systems of women with HIV react positively to the human papillomavirus vaccine.

When testing patients for HIV, healthcare professionals should also test for sexually transmitted infections.

Within the next two years, treatments for hepatitis C with 95% cure rates that are all-oral, interferon-free, and effective within 12 weeks or less with negligible side effects will be readily available.

Men who are HIV-positive and enrolled in substance use treatment programs report reduced sexual risky behavior and stimulant use.

By growing vaginal skin cells outside of the human body, a team of researchers has pinpointed which bacteria fight against HIV.

For patients with HIV, there is a negative correlation between drinking frequency and antiretroviral therapy (ART) adherence, according to a cross-sectional study published online in Patient Preference and Adherence.

Study results show hepatic decompensation is more common in people who have both HIV and hepatitis C virus (HCV) compared to those infected only with HCV, an indication that early HCV treatment among coinfected patients is needed.

The United States government has lifted a federal ban on the transplantation of organs from deceased HIV-infected donors to HIV-infected recipients, and the ramifications of this action are expected to be great.

A protein naturally found in breast milk that's responsible for fetal development and wound healing could also have neutralizing effects against HIV-1, according to a recent study.

Hepatitis C, HIV, C. diff, and other infectious diseases can present complex clinical challenges in the hospital setting.

A novel direct-acting antiviral (DAA) targeting a protein associated with hepatitis C (HCV) also has antiviral activity against HIV-1 and shows benefit in co-infected individuals when added to pegylated interferon and ribavirin treatment (PR).

Results from a clinical trial designed to evaluate the effectiveness of a hepatitis C educational program delivered by the Hepatology Centers of Educational Expertise, a hepatologist-led working group dedicated to educating healthcare professionals on the latest developments in the management of chronic liver disease.

Long-term usage of crofelemer, a drug that relieves noninfectious diarrhea symptoms in patients with HIV, was well-tolerated and produced few adverse events in a recent study.

Shortening IFN-free combination treatment of chronic HCV to 16 weeks and eliminating the induction dose of deleobuvir reduces viral load and treatment-induced side effects, according to a recent clinical trial.